<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1137-6627</journal-id>
<journal-title><![CDATA[Anales del Sistema Sanitario de Navarra]]></journal-title>
<abbrev-journal-title><![CDATA[Anales Sis San Navarra]]></abbrev-journal-title>
<issn>1137-6627</issn>
<publisher>
<publisher-name><![CDATA[Gobierno de Navarra. Departamento de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1137-66272020000100009</article-id>
<article-id pub-id-type="doi">10.23938/assn.0858</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Adherencia al tratamiento con agentes estimulantes de la eritropoyesis]]></article-title>
<article-title xml:lang="en"><![CDATA[Adherence to treatment with erythropoiesis stimulating agents]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Díez]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Navarro Aznárez]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lou Arnal]]></surname>
<given-names><![CDATA[L.M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Miguel Servet Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario Miguel Servet Servicio de Nefrología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<volume>43</volume>
<numero>1</numero>
<fpage>81</fpage>
<lpage>85</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1137-66272020000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1137-66272020000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1137-66272020000100009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Fundamento Determinar la adherencia al tratamiento con agentes estimulantes de la eritropoyesis (AEE) en pacientes con anemia asociada a enfermedad renal crónica (ERC), y valorar su relación con la respuesta frente a estos AEE.  Material y métodos Estudio retrospectivo, observacional, de una cohorte de 198 pacientes con ERC que iniciaron tratamiento con epoetina-&#946; o darbepoetina-&#945;, seguidos durante dos años. Se registraron variables basales, de efectividad (% de consecución de objetivos de hemoglobina (Hb), incremento porcentual de Hb) y adherencia (tasa de posesión de medicación). Se consideró no adherente al paciente cuya adherencia fue &lt;90%.  Resultados La adherencia global fue 89,6%, ligeramente superior en darbepoetina-&#945; que en epoetina-&#946;; el 8,6% de los pacientes fueron no adherentes. El 87% cumplió el objetivo de Hb. Los valores de respuesta a AEE no variaron en función del grado de adherencia al tratamiento.  Conclusiones La adherencia al tratamiento con AEE fue buena, sin diferencias según la respuesta.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background To establish adherence to treatment with erythropoiesis stimulating agents (ESA) in patients with anemia associated to chronic kidney disease (CKD), and analyze its relationship to response to ESA.  Methods Retrospective study of a cohort of 198 patients with CKD who started treatment with epoetin-&#946; or darbepoetin-&#945;, followed for two years. Basal characteristics, effectiveness (% of hemoglobin (Hb) target attainment, percentage increase of Hb) and adherence (medication possession rate) were registered. A non-adherent patient was one whose mean adherence was &lt;90%.  Results Average global adhesion was 89.6%, slightly higher in treatment with darbepoetin-&#945; than with epoetin-&#946;; 8.6% of patients were non-adherents. Hb target was accomplished in 87% cases. Level of response to ESA treatment was independent of the degree of adherence to treatment.  Conclusions Adherence to ESA treatment was good, without differences related to degree of response.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Anemia]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad renal crónica]]></kwd>
<kwd lng="es"><![CDATA[Adherencia terapéutica]]></kwd>
<kwd lng="es"><![CDATA[Eritropoyetina]]></kwd>
<kwd lng="es"><![CDATA[Epoetina alfa]]></kwd>
<kwd lng="en"><![CDATA[Anemia]]></kwd>
<kwd lng="en"><![CDATA[Chronic kidney failure]]></kwd>
<kwd lng="en"><![CDATA[Therapeutic adherence]]></kwd>
<kwd lng="en"><![CDATA[Erythropoietin]]></kwd>
<kwd lng="en"><![CDATA[Epoetin alfa]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cases]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Egocheaga]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Tranchec]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pallarés]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ojeda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Górriz]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<source><![CDATA[Nefrología]]></source>
<year>2018</year>
<volume>3</volume>
<page-range>8-12</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Documento de la Sociedad Española de Nefrología sobre las guías KDIGO para la evaluación y el tratamiento de la enfermedad renal crónica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorostidi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Santamaría]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Alcázar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Fresnedo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Galcerán]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Goicoechea]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Nefrología]]></source>
<year>2014</year>
<volume>34</volume>
<page-range>302-16</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Manejo de la anemia en la enfermedad renal crónica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[López Gómez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Nefrología]]></source>
<year>2008</year>
<volume>28</volume>
<page-range>63-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="book">
<collab>Amgen Europe</collab>
<source><![CDATA[Ficha técnica de Aranesp(r)]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Breda ]]></publisher-loc>
<publisher-name><![CDATA[Amgen Europe]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="book">
<collab>Roche</collab>
<source><![CDATA[Ficha técnica de Neorecormon(r)]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Grenzach-Wyhlen ]]></publisher-loc>
<publisher-name><![CDATA[Roche Registration GmbH]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Erythropoiesis-stimulating agent hyporesponsiveness]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Pollock]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Macdougall]]></surname>
<given-names><![CDATA[IC]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephrology]]></source>
<year>2007</year>
<volume>12</volume>
<page-range>321-30</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Moran]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hlatky]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lafayette]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2009</year>
<volume>24</volume>
<page-range>1956-62</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Latest strategy in renal anemia management in peritoneal dialysis patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
</person-group>
<source><![CDATA[Perit Dial Int]]></source>
<year>2008</year>
<volume>28</volume>
<page-range>S76-80</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Revisión de test de medición del cumplimiento terapéutico utilizados en la práctica clínica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Chamorro]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[García-Jiménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Chamorro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Faus]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Aten Primaria]]></source>
<year>2017</year>
<volume>49</volume>
<page-range>459-64</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Métodos para medir la adherencia terapéutica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pagès-Puigdemont]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Valverde-Merino]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<source><![CDATA[Ars Pharm]]></source>
<year>2018</year>
<volume>59</volume>
<page-range>163-72</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease]]></article-title>
<collab>Kidney Disease: Improving Global Outcomes Anemia Work Group</collab>
<source><![CDATA[Kidney Inter Suppl]]></source>
<year>2012</year>
<volume>2</volume>
<page-range>279-335</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparing adherence and persistence across 6 chronic medication classes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeaw]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Benner]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Walt]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Sian]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
</person-group>
<source><![CDATA[J Manag Care Pharm]]></source>
<year>2009</year>
<volume>15</volume>
<page-range>728-40</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Factors influencing erythropoietin compliance in peritoneal dialysis patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wazny]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Stojimirovic]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Heidenheim]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Blake]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2002</year>
<volume>40</volume>
<page-range>623-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Eficiencia de la administración mensual subcutánea de metoxi-polietilenglicol epoetina ß (Mircera(r)) en pacientes estables en hemodiálisis previamente tratados con eritropoyetina semanal]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albero Molina]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[López-Menchero Martínez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Del Pozo Fernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Fernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Rodríguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Dial Traspl]]></source>
<year>2013</year>
<volume>34</volume>
<page-range>93-100</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of early conrrection of anemia on the progression of CKD]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rossert]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roger]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Horl]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Rouqueray]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gassmann-Mayer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2006</year>
<volume>47</volume>
<page-range>738-50</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
